Targeting death-inducing receptors in cancer therapy
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apoptosis in the Pathogenesis and Treatment of Disease
Thompson, C. B. (1995) · Science · doi:10.1126/science.7878464 · Cited by 6,524 · cited 1×
“…superfamily in cancer Programmed cell death (apoptosis) is a controlled cellular mechanism, where the organism maintains cellular homeostasis in normal tissue compartments and eliminates disordered cells (Steller, 1995; Thompson, 1995; Hanahan and Weinberg, 2000; Danial and Korsmeyer, 2004).”
BackgroundDeath Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866 · cited 1×
“The TNF superfamily is characterized by a sequence of two to five cysteine-rich extracellular repeats (Figure 1) (Ashkenazi and Dixit, 1998; Ashkenazi, 2002).”
BackgroundDanial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 7×
“The MD5-1-induced antitumor effect was demonstrated to depend mainly on direct apoptosis induction, rather than antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC), as DR5expressing and Fas-associated death domain (FADD)like IL-1b-converting enzyme (FLICE) inhibitory protein (FLI…”
BackgroundInfluentialTumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497 · cited 2×
“…in mice and non-human primates have shown that the administration of soluble forms of rTRAIL suppressed the growth of TRAIL-sensitive human tumor xenografts, with no apparent systemic toxicity (Ashkenazi et al., 1999; Walczak et al., 1999), supporting the potential utility of rTRAIL in vivo.”
BackgroundSafety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Lethal effect of the anti-Fas antibody in mice
Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., & Nagata, S. (1993) · Nature · doi:10.1038/364806a0 · Cited by 1,881 · cited 2×
“…Fas or Apo1, is the best-known death receptor belonging to the TNF receptor superfamily (Schmitz et al., 2000; Timmer et al., 2002); however, before long it was appreciated that systemic treatment with Fas-targeting therapy causes severe liver damage (Ogasawara et al., 1993; Galle et al., 1995).”
BackgroundNatural selection of tumor variants in the generation of “tumor escape” phenotypes
Khong, H. T., & Restifo, N. P. (2002) · Nature Immunology · doi:10.1038/ni1102-999 · Cited by 1,058
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940 · cited 1×
“Blockade of CTLA-4 mediated inhibitory signals to tumor-specific CD8þ T cells and immune suppression by regulatory T cells is another interesting approach to further augment mAb-based antitumor effects (Egen et al., 2002).”
BackgroundRituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
Smith, M. R. (2003) · Oncogene · doi:10.1038/sj.onc.1206939 · Cited by 835 · cited 2×
“…used to treat B-cell chronic lymphocytic leukemia and non-Hodgkin’s lymphoma; although this mAb requires Fc receptor crosslinking and exhibits its antitumor effects through multiple mechanisms, it has also been reported to induce apoptosis (Cragg et al., 1999; Reed et al., 2002; Smith, 2003).”
BackgroundApoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis
Chawla-Sarkar, M., Lindner, D. J., Liu, Y.-F., Williams, B. R., Sen, G. C., Silverman, R. H., & Borden, E. C. (2003) · Apoptosis · doi:10.1023/a:1023668705040 · Cited by 829
Takimoto, R., & El-Deiry, W. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203489 · Cited by 360 · cited 1×
“…induced tumor cell apoptosis in vitro and in vivo (Sheikh et al., 1998; Ashkenazi et al., 1999; Gliniak and Le, 1999; Chinnaiyan et al., 2000; Takimoto and El-Deiry, 2000; Chuntharapai et al., 2001; LeBlanc et al., 2002; Wajant et al., 2002; Buchsbaum et al., 2003; Ohtsuka et al., 2003;…”
BackgroundFc receptors are required in passive and active immunity to melanoma
Clynes, R., Takechi, Y., Moroi, Y., Houghton, A., & Ravetch, J. V. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.652 · Cited by 321
Pukac, L., Kanakaraj, P., Humphreys, R., Alderson, R., Bloom, M., Sung, C., Riccobene, T., Johnson, R., Fiscella, M., Mahoney, A., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602487 · Cited by 306 · cited 4×
“…it has been reported that agonistic anti-human DR4 or DR5 mAbs exhibited potent tumoricidal activities against human tumor xenografts in nude or SCID mice without apparent toxicity (Griffith et al., 1999; Chuntharapai et al., 2001; Ichikawa et al., 2001; Motoki et al., 2005; Pukac et al., 2005).”
BackgroundInfluential
Cited by
Interleukin-21: Basic Biology and Implications for Cancer and Autoimmunity
Spolski, R., & Leonard, W. J. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090316 · Cited by 696
Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease
Takeda, K., Kojima, Y., Ikejima, K., Harada, K., Yamashina, S., Okumura, K., Aoyama, T., Frese, S., Ikeda, H., Haynes, N. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802702105 · Cited by 148
“Recombinant TRAIL and anti-DR4 or DR5 monoclonal antibodies (mAbs) were reported to be substantially tumoricidal in mice without apparent toxicity (10–14), and have now started to be applied in cancer therapy (3, 9, 15, 16).”
BackgroundSelf-citationPare, R., Soon, P. S., Shah, A., & Lee, C. S. (2019) · PLOS ONE · doi:10.1371/journal.pone.0214604 · Cited by 23
Metadata
- Authors
- Takeda, K., Stagg, J., Yagita, H., Okumura, K., & Smyth, M. J.
- Venue
- Oncogene
- Published
- 2007-05-28
- Volume
- 26
- Issue
- 25
- Pages
- 3745-3757
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1996874641
- Cited by
- 186
- References
- 15
- FWCI
- 8.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.